92-OR

Abstract

Objectives To investigate the clinical usefulness of Placental growth factor (PlGF) testing, prior to 35 weeks and at all gestations, as a marker of subsequent disease and harm in placental insufficiency conditions (specifically pre-eclampsia and intrauterine growth restriction). Methods A prospective cohort study was conducted, blinded to treating clinicians, analyzing PlGF levels in women being investigated for pre-eclampsia. Serum PlGF levels were measured in 125 pregnancies, gestations ranging from 28 to 42 weeks. 46 patients developed pre-eclampsia (diagnosis based on SOMANZ criteria) and 28 IUGR (birth weight 100 pg/ml, and also stratified to gestation specific reference ranges. Results For patients tested at all gestations, a result of p = p = 0.0002) and an almost seven times increased risk of developing pre-eclampsia or growth restriction (LR = 6.7, p = 0.0002). Whilst for patients tested prior to 35 weeks, a result of >100 pg/ml, indicates a six times decreased risk of developing pre-eclampsia (LR = 6.0, p = 0.0021), and an almost nine times decreased risk of developing pre-eclampsia with growth restriction (LR = 8.7, p = Conclusions Preliminary results indicated that PlGF testing at all gestations is a useful marker for the development of placental insufficiency conditions. Prior to 35 weeks, its value appears to lie as a negative marker. Further testing is being done to analyze the correlation between PlGF level and disease severity and timing to delivery. Disclosures A. Woods: None. G. Dekker: None.